Grants & Programs

Entering the Era of Combination Therapies: Practical Implementation

Date:
April 25, 2013
Time:
06:00 AM
Location:
Willard InterContinental, Washington, DC
View Map

The 2013 Scientific Colloquium of the CRI Cancer Immunotherapy Consortium, Entering the Era of Combination Therapies: Practical Implementation, brought together leaders from the regulatory, scientific, and business communities to present new methodological tools, leading-edge scientific data from ongoing combination studies, and innovative models of academic-industry collaboration that are helping to overcome challenges to optimizing combination cancer therapies for the benefit of patients.
 

Introduction

  • Axel Hoos, GlaxoSmithKline
     

Keynote Address

  • Guido Kroemer, INSERM U848, Institut Gustave-Roussy and University of Paris Descartes
     

The Science of Combinations: Methods

  • Donald Berry, The University of Texas MD Anderson Cancer Center
  • Tarek Fahmy, Yale University
  • Hans Winkler, GNS Healthcare
  • Cassian Yee, The University of Texas MD Anderson Cancer Center


The Science of Combinations: Pre-clinical Results

  • Charles Drake, Johns Hopkins University
  • Samir Khleif, Georgia Regents University
  • Holbrook Kohrt, Stanford University
  • Kalet Leon, Center of Molecular Immunology
  • Hyam Levitsky, Roche Glycart AG
  • Brian Lichty, McMaster University
  • Ira Mellman, Genentech
  • Hiroyoshi Nishikawa, Osaka University
  • Protul Shrikant, Roswell Park Cancer Institute
  • Mark Smyth, Queensland Institute of Medical Research


The Science of Combinations: Clinical Results

  • Tania Crombet Ramos, Center of Molecular Immunology
  • Ronald Levy, Stanford University School of Medicine
  • Marc Mansour, Immunovaccine, Inc.


Immune Effects of Non-immunological Pathways

  • Margaret Callahan, Memorial Sloan-Kettering Cancer Center
  • Padmanee Sharma, The University of Texas MD Anderson Cancer Center


Practical Implementation of Combination Therapy Programs

  • Jeffrey Bockman, Defined Health
  • James Doroshow, National Cancer Institute, NIH
  • Thomas Hinz, Paul-Ehrlich-Institut
  • Adam Kolom, CVAF/Cancer Research Institute
  • Amy McKee, Food and Drug Administration
  • Stephen Sands, Roche Partnering


Immune Monitoring

  • Cedrik Britten, TRON
  • Angelica Cazaly, University of Southampton School of Medicine
  • Yuji Heike, National Cancer Center Japan
  • Sylvia Janetzki, ZellNet Consulting, Inc.
  • Pia Kvistborg, Netherlands Cancer Institute
  • Holden Maecker, Stanford University
  • Henrik Pedersen, Immudex
  • Elizabeth Reap, Duke University

 


Contact Us

Want to learn more about the Cancer Immunotherapy Consortium? Contact a CIC representative at consortium@cancerresearch.org or (212) 688-7515.